Compare
Abpro Holdings, Inc. vs Brainstorm Cell Therapeutics Inc. vs Zeo ScientifiX, Inc. vs Zivo Bioscience, Inc.
| Latest fiscal year | Abpro Holdings, Inc. ABPO | Brainstorm Cell Therapeutics Inc. BCLI | Zeo ScientifiX, Inc. ZEOX | Zivo Bioscience, Inc. ZIVOLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-10-31 | 2024-12-31 |
| Revenue | n/a | n/a | $5.20M | $157.2K |
| Revenue growth (YoY) | n/a | n/a | +12.5% | +468.6% |
| Gross margin | n/a | n/a | 82.1% | 31.1% |
| Operating margin | n/a | n/a | -103.6% | n/m |
| Net margin | n/a | n/a | -106.2% | n/m |
| Net income | -$2.89M | -$10.31M | -$5.52M | -$13.38M |
| EPS (Diluted) | -$1.30 | -$1.11 | -$0.86 | -$4.23 |
| Operating cash flow | -$6.01M | -$6.97M | -$718.0K | -$4.31M |
| Free cash flow | n/a | n/a | -$741.0K | n/a |
| Cash & equivalents | n/a | $29.0K | n/a | n/a |
| Total assets | $1.06M | $1.02M | $1.53M | $1.64M |
| Total liabilities | n/a | $11.01M | $2.95M | $2.16M |
| Shareholders' equity | -$8.83M | -$9.98M | -$1.42M | -$514.9K |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 2.73M | 11.03M | 6.75M | 3.62M |
Revenue, most recent five fiscal years
| Fiscal year | Abpro Holdings, Inc. | Brainstorm Cell Therapeutics Inc. | Zeo ScientifiX, Inc. | Zivo Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $183.0K Ended 2024-12-31 | n/a | $5.20M Ended 2025-10-31 | $157.2K Ended 2024-12-31 |
| 1 year earlier | $122.0K Ended 2023-12-31 | n/a | $4.62M Ended 2024-10-31 | $27.6K Ended 2023-12-31 |
| 2 years earlier | n/a | n/a | $4.56M Ended 2023-10-31 | $0 Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $6.49M Ended 2022-10-31 | $0 Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $5.60M Ended 2021-10-31 | $20.0K Ended 2020-12-31 |